 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mMINOCYCLINE[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mMINOCYCLINE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Provide information about the drug Minocycline."[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Minocycline"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE Minocycline hydrochloride extended-release tablets is tetracycline-class drug indicated to treat only inflammatory lesions of [0m
[31mnon-nodular moderate to severe acne vulgaris in patients [0m[1;31m12[0m[31m years of age and older. [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Indication Minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory [0m
[31mlesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;31m12[0m[31m years of age and older. [0m[1;31m1.2[0m[31m Limitations of Use Minocycline hydrochloride extended-release tablets did not demonstrate any effect [0m
[31mon non-inflammatory acne lesions. Safety of minocycline hydrochloride extended-release tablets has not been established beyond [0m[1;31m12[0m[31m weeks of use. This formulation of minocycline has not been evaluated [0m
[31min the treatment of infections [0m[31m. MINOCYCLINE: indications_and_usage: To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, [0m
[31mminocycline hydrochloride extended-release tablets should be used only as indicated [0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: description: [0m[1;31m11[0m[31m DESCRIPTION Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [0m
[1;31m[[0m[31m4S-[0m[1;31m([0m[31m4α,4aα,5aα,12aα[0m[1;31m)[0m[1;31m][0m[1;31m-4[0m[31m,[0m[1;31m7[0m[31m-[0m[1;31mBis[0m[1;31m([0m[31mdimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m,12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-tetrahydroxy-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-dioxo-[0m[1;31m2[0m[31m-naphthacenecarboxamide mono hydrochloride. The structural formula is represented [0m
[31mbelow: Minocycline hydrochloride extended-release tablets for oral administration contain minocycline hydrochloride, USP equivalent to [0m[1;31m45[0m[31m mg, [0m[1;31m90[0m[31m mg, or [0m[1;31m135[0m[31m mg of minocycline. MINOCYCLINE: description:[0m
[31mIn addition, [0m[1;31m45[0m[31m mg, [0m[1;31m90[0m[31m mg, and [0m[1;31m135[0m[31m mg tablets contain the following inactive ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, and magnesium stearate. The [0m[1;31m45[0m[31m mg [0m
[31mextended-release tablets also contain opadry grey, which contains: titanium dioxide, triacetin, iron oxide black, and iron oxide yellow. The [0m[1;31m90[0m[31m mg extended-release tablets also contain opadry orange, [0m
[31mwhich contains: titanium dioxide, triacetin, iron oxide yellow, FD&C yellow # [0m[1;31m6[0m[31m, and iron oxide red. The [0m[1;31m135[0m[31m mg extended-release tablets also contain opadry yellow, which contains: titanium dioxide, [0m
[31mtriacetin and iron oxide yellow. MINOCYCLINE: description: structure formula         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION [0m[1;31m[[0m[31mSee FDA-approved patient labeling [0m[1;31m([0m[31mPatient Information[0m[1;31m)[0m[1;31m][0m[31m Patients taking minocycline hydrochloride extended-release [0m
[31mtablets should receive the following information and instructions: • Minocycline hydrochloride extended-release tablets should not be used by pregnant women or women attempting to conceive a child [0m[31m. •[0m
[31mIt is recommended that minocycline hydrochloride extended-release tablets not be used by men who are attempting to father a child [0m[31m. • Patients should be advised that pseudomembranous colitis can occur[0m
[31mwith minocycline therapy. If patients develop watery or bloody stools, they should seek medical attention. • Patients should be counseled about the possibility of hepatotoxicity. MINOCYCLINE: [0m
[31minformation_for_patients: Patients should seek medical advice if they experience symptoms which can include loss of appetite, tiredness, diarrhea, skin turning yellow, bleeding easily, confusion, and [0m
[31msleepiness. • Patients who experience central nervous system symptoms [0m[31m should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. Patients should seek [0m
[31mmedical help for persistent headaches or blurred vision. • Concurrent use of tetracycline may render oral contraceptives less effective [0m[31m. • Autoimmune syndromes, including drug-induced lupus-like [0m
[31msyndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline-class drugs, including minocycline. Symptoms may be manifested by arthralgia, fever, rash and [0m
[31mmalaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help. MINOCYCLINE: information_for_patients: • Patients should be counseled about [0m
[31mdiscoloration of skin, scars, teeth or gums that can arise from minocycline therapy. • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking [0m
[31mtetracyclines, including minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight [0m[1;31m([0m[31mtanning beds or UVA/B treatment[0m[1;31m)[0m[31m while using minocycline. If patients need to be [0m
[31moutdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be [0m
[31mdiscontinued at the first evidence of skin erythema. • Minocycline hydrochloride extended-release tablets should be taken exactly as directed. Skipping doses or not completing the full course of [0m
[31mtherapy may decrease the effectiveness of the current treatment course and increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the [0m
[31mfuture.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: • Stop taking minocycline hydrochloride extended-release tablets and get medical help right away if you have any of these symptoms: ∘ skin rash, [0m
[31mhives, sores in your mouth, or your skin blisters and peels ∘ swelling of your face, eyes, lips, tongue, or throat ∘ trouble swallowing or breathing ∘ blood in your urine ∘ fever, yellowing of the [0m
[31mskin or the whites of your eyes, dark colored urine ∘ pain on the right side of the stomach area [0m[1;31m([0m[31mabdominal pain[0m[1;31m)[0m[31m ∘ chest pain or abnormal heartbeats ∘ swelling in your legs, ankles and feet ∘ [0m
[31mdarkening of your nails, skin, eyes, scars, teeth, and gums. The most common side effects of minocycline hydrochloride extended-release tablets include: • headache • tiredness • dizziness or spinning [0m
[31mfeeling • itching Call your doctor if you have a side effect that bothers you or that does not go away. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to check you for side effects [0m
[31mduring treatment with minocycline hydrochloride extended-release tablets. These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask your doctor or pharmacist for [0m
[31mmore information. Call your doctor for medical advice about side effects. You may report side effects to Sandoz Inc. at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How should I store minocycline [0m
[31mhydrochloride extended-release tablets? • Store minocycline hydrochloride extended-release tablets at 20º to 25ºC [0m[1;31m([0m[31m68º to 77ºF[0m[1;31m)[0m[31m [0m[31m. • Keep minocycline hydrochloride extended-release tablets in the [0m
[31mcontainer that it comes in and keep container tightly closed. • Keep minocycline hydrochloride extended-release tablets dry. MINOCYCLINE: spl_patient_package_insert: Keep minocycline hydrochloride [0m
[31mextended-release tablets and all medicines out of the reach of children. General Information about minocycline hydrochloride extended-release tablets Medicines are sometimes prescribed for purposes [0m
[31mother than those listed in the Patient Information Leaflet. Do not use minocycline hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give minocycline [0m
[31mhydrochloride extended-release tablets to other people, even if they have the same symptoms you have. It may harm them. This Patient Information leaflet summarizes the most important information about[0m
[31mminocycline hydrochloride extended-release tablets. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about minocycline hydrochloride [0m
[31mextended-release tablets that is written for health professionals. For more information, call Sandoz Inc. MINOCYCLINE: spl_patient_package_insert: at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m What are the ingredients in [0m
[31mminocycline hydrochloride extended-release tablets? Active Ingredient: Minocycline Hydrochloride, USP Inactive Ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, and magnesium [0m
[31mstearate. The [0m[1;31m45[0m[31m mg extended-release tablets also contain opadry grey, which contains: titanium dioxide, triacetin, iron oxide black, and iron oxide yellow. The [0m[1;31m90[0m[31m mg extended-release tablets also [0m
[31mcontain opadry orange, which contains: titanium dioxide, triacetin, iron oxide yellow, FD&C yellow #[0m[1;31m6[0m[31m, and iron oxide red. The [0m[1;31m135[0m[31m mg extended-release tablets also contain opadry yellow, which [0m
[31mcontains: titanium dioxide, triacetin and iron oxide yellow. MINOCYCLINE: spl_patient_package_insert: Manufactured by: USV Private Limited, OIDC, Mahatma Gandhi Udyog Nagar, Dabhel, Daman [0m[1;31m396210[0m[31m, [0m
[31mIndia for Sandoz Inc., Princeton, NJ [0m[1;31m08540[0m[31m Rev.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics The pharmacodynamics of minocycline hydrochloride extended-release tablets for the treatment of acne are unknown.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: Patient Information Minocycline Hydrochloride Extended-Release Tablets Rx only Read this patient information leaflet that comes with minocycline [0m
[31mhydrochloride extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about [0m
[31myour condition or treatment. What are minocycline hydrochloride extended-release tablets? Minocycline hydrochloride is tetracycline-class drug. Minocycline hydrochloride extended-release tablets are [0m
[31mprescription medicine used to treat pimples and red bumps [0m[1;31m([0m[31mnon-nodular inflammatory lesions[0m[1;31m)[0m[31m that happen with moderate to severe acne vulgaris in people [0m[1;31m12[0m[31m years and older. Minocycline hydrochloride [0m
[31mextended-release tablets are not effective for acne that is not red-looking [0m[1;31m([0m[31mthis means acne that is not inflammatory[0m[1;31m)[0m[31m. MINOCYCLINE: spl_patient_package_insert: It is not known if minocycline [0m
[31mhydrochloride extended-release tablets are: • safe for use longer than [0m[1;31m12[0m[31m weeks. • safe and effective for the treatment of infections. • safe and effective in children under the age of [0m[1;31m12[0m[31m years. Who [0m
[31mshould not take minocycline hydrochloride extended-release tablets? Do not take minocycline hydrochloride extended-release tablets if you are allergic to tetracycline-class drugs. Ask your doctor or [0m
[31mpharmacist for a list of these medicines if you are not sure. What should I tell my doctor before taking minocycline hydrochloride extended-release tablets? Before you take minocycline hydrochloride [0m
[31mextended-release tablets, tell your doctor if you: • have kidney problems. Your doctor may prescribe a lower dose of medicine for you. • have liver problems. • have diarrhea or watery stools. • have [0m
[31mvision problems. • plan to have surgery with general anesthesia. • have any other medical conditions. MINOCYCLINE: spl_patient_package_insert: • are a male, and you and your female partner are trying [0m
[31mto conceive a baby. You should not take minocycline hydrochloride extended-release tablets • are pregnant or plan to become pregnant. Minocycline hydrochloride extended-release tablets may harm your [0m
[31munborn baby. Taking minocycline hydrochloride extended-release tablets while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Talk to your doctor before [0m
[31mtaking minocycline hydrochloride extended-release tablets if you plan to become pregnant, or if you are already taking minocycline hydrochloride extended-release tablets and plan to become pregnant. [0m
[31mStop taking minocycline hydrochloride extended-release tablets and call your doctor right away if you become pregnant while taking minocycline hydrochloride extended-release tablets. • are [0m
[31mbreastfeeding or plan to breastfeed. Minocycline hydrochloride passes into your milk and may harm your baby.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Minocycline hydrochloride extended-release tablets are a tetracycline-class drug indicated for the treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in [0m
[32mpatients [0m[1;32m12[0m[32m years of age and older. The safety of minocycline hydrochloride extended-release tablets has not been established beyond [0m[1;32m12[0m[32m weeks of use, and it has not been evaluated in the treatment of [0m
[32minfections. It is not effective for non-inflammatory acne lesions. The drug should not be used by pregnant women, women attempting to conceive, or men who are attempting to father a child. Patients [0m
[32mshould be aware of potential side effects such as pseudomembranous colitis, hepatotoxicity, central nervous system symptoms, autoimmune syndromes, discoloration of skin, scars, teeth, or gums, and [0m
[32mphotosensitivity. Minocycline hydrochloride extended-release tablets come in doses equivalent to [0m[1;32m45[0m[32m mg, [0m[1;32m90[0m[32m mg, or [0m[1;32m135[0m[32m mg of minocycline and contain various inactive ingredients. The pharmacodynamics [0m
[32mof minocycline for the treatment of acne are unknown.[0m

[32mSOURCE: Minocycline label[0m
[32mEXTRACT_START_END: [0m[1;32m1[0m[32m INDICATIONS AND USAGE Minocycline hydrochloride[0m[32m...[0m[32mtreatment of infections [0m[32m.[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Minocycline hydrochloride extended-release tablets are a [0m
[34mtetracycline-class drug indicated for the treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;34m12[0m[34m years of age and older. The safety of minocycline [0m
[34mhydrochloride extended-release tablets has not been established beyond [0m[1;34m12[0m[34m weeks of use, and it has not been evaluated in the treatment of infections. It is not effective for non-inflammatory acne [0m
[34mlesions. The drug should not be used by pregnant women, women attempting to conceive, or men who are attempting to father a child. Patients should be aware of potential side effects such as [0m
[34mpseudomembranous colitis, hepatotoxicity, central nervous system symptoms, autoimmune syndromes, discoloration of skin, scars, teeth, or gums, and photosensitivity. Minocycline hydrochloride [0m
[34mextended-release tablets come in doses equivalent to [0m[1;34m45[0m[34m mg, [0m[1;34m90[0m[34m mg, or [0m[1;34m135[0m[34m mg of minocycline and contain various inactive ingredients. The pharmacodynamics of minocycline for the treatment of acne are [0m
[34munknown.[0m

[34mSOURCE: Minocycline label[0m
[34mEXTRACT_START_END: [0m[1;34m1[0m[34m INDICATIONS AND USAGE Minocycline hydrochloride[0m[34m...[0m[34mtreatment of infections [0m[34m.[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does Minocycline increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Minocycline"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: warnings_and_cautions: This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has [0m
[31malso been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT. C. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula [0m
[31mgrowth rate has been observed in premature human infants given oral tetracycline in doses of [0m[1;31m25[0m[31m mg/kg every [0m[1;31m6[0m[31m hours. This reaction was shown to be reversible when the drug was discontinued. Results of[0m
[31manimal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has [0m
[31mbeen noted in animals treated early in pregnancy [0m[31m [0m[1;31m5[0m[31m. MINOCYCLINE: warnings_and_cautions: [0m[1;31m2[0m[31m Pseudomembranous Colitis Clostridium difficile associated diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m has been reported with nearly all [0m
[31mantibacterial agents, including minocycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to [0m
[31movergrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as [0m
[31mthese infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical [0m
[31mhistory is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed [0m
[31magainst C. difficile may need to be discontinued. MINOCYCLINE: warnings_and_cautions: Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and [0m
[31msurgical evaluation should be instituted as clinically indicated. [0m[1;31m5.3[0m[31m Hepatotoxicity Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic [0m
[31mfailure [0m[1;31m([0m[31msometimes fatal[0m[1;31m)[0m[31m have been reported with minocycline use in the treatment of acne. [0m[1;31m5.4[0m[31m Metabolic Effects The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this[0m
[31mis not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class drugs may lead to azotemia, hyperphosphatemia, and [0m
[31macidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. MINOCYCLINE: warnings_and_cautions: [0m
[31mUnder such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable. [0m[1;31m5.5[0m[31m Central Nervous System Effects Central [0m
[31mnervous system side effects including light-headedness, dizziness or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving [0m
[31mvehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually rapidly disappear when the drug is discontinued. [0m[1;31m5.6[0m[31m Benign Intracranial [0m
[31mHypertension Pseudotumor cerebri [0m[1;31m([0m[31mbenign intracranial hypertension[0m[1;31m)[0m[31m in adults and adolescents has been associated with the use of tetracyclines. Minocycline has been reported to cause or precipitate [0m
[31mpseudotumor cerebri, the hallmark of which is papilledema. Clinical manifestations include headache and blurred vision. MINOCYCLINE: warnings_and_cautions: Bulging fontanels have been associated with [0m
[31mthe use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after discontinuation of treatment, the possibility for permanent sequelae such as visual loss that may [0m
[31mbe permanent or severe exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines. If visual disturbance occurs during treatment, patients should[0m
[31mbe checked for papilledema. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. [0m[1;31m5.7[0m[31m Autoimmune [0m
[31mSyndromes Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like [0m
[31msyndrome, autoimmune hepatitis and vasculitis.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: overdosage: [0m[1;31m10[0m[31m OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Minocycline is not removed in significant [0m
[31mquantities by hemodialysis or peritoneal dialysis.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: [0m[1;31m13.1[0m[31m Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a carcinogenicity study in which [0m
[31mminocycline HCl was orally administered to male and female rats once daily for up to [0m[1;31m104[0m[31m weeks at dosages up to [0m[1;31m200[0m[31m mg/kg/day, minocycline HCl was associated in both genders with follicular cell [0m
[31mtumors of the thyroid gland, including increased incidences of adenomas, carcinomas and the combined incidence of adenomas and carcinomas in males, and adenomas and the combined incidence of adenomas [0m
[31mand carcinomas in females. In a carcinogenicity study in which minocycline HCl was orally administered to male and female mice once daily for up to [0m[1;31m104[0m[31m weeks at dosages up to [0m[1;31m150[0m[31m mg/kg/day, exposure [0m
[31mto minocycline HCl did not result in a significantly increased incidence of neoplasms in either males or females. MINOCYCLINE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Mutagenesis [0m
[31mMinocycline was not mutagenic in vitro in a bacterial reverse mutation assay [0m[1;31m([0m[31mAmes test[0m[1;31m)[0m[31m or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not [0m
[31mclastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test. Impairment of Fertility Male and female reproductive performance in rats was unaffected by oral [0m
[31mdoses of minocycline of up to [0m[1;31m300[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in up to approximately [0m[1;31m40[0m[31m times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline [0m
[31mhydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: However, oral administration of [0m[1;31m100[0m[31m or [0m[1;31m300[0m[31m mg/kg/day of minocycline to male rats [0m
[1;31m([0m[31mresulting in approximately [0m[1;31m15[0m[31m to [0m[1;31m40[0m[31m times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m adversely [0m
[31maffected spermatogenesis. Effects observed at [0m[1;31m300[0m[31m mg/kg/day included a reduced number of sperm cells per gram of epididymis, an apparent reduction in the percentage of sperm that were motile, and [0m[1;31m([0m[31mat [0m
[1;31m100[0m[31m and [0m[1;31m300[0m[31m mg/kg/day[0m[1;31m)[0m[31m increased numbers of morphologically abnormal sperm cells. Morphological abnormalities observed in sperm samples included absent heads, misshapen heads, and abnormal flagella. [0m
[31mLimited human studies suggest that minocycline may have a deleterious effect on spermatogenesis. Minocycline hydrochloride extended-release tablets should not be used by individuals of either gender [0m
[31mwho are attempting to conceive a child.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: adverse_reactions: Table [0m[1;31m2[0m[31m: Selected Treatment-Emergent Adverse Reactions in at least [0m[1;31m1[0m[31m% of Clinical Trial Subjects Adverse Reactions Minocycline Hydrochloride Extended-Release [0m
[31mTablets [0m[1;31m([0m[1;31m1[0m[31m mg/kg[0m[1;31m)[0m[31m [0m[31mN[0m[31m=[0m[1;31m674[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Placebo [0m[31mN[0m[31m=[0m[1;31m364[0m[1;31m([0m[31m%[0m[1;31m)[0m[31m At least one treatment-emergent event [0m[1;31m379[0m[1;31m([0m[1;31m56[0m[1;31m)[0m[31m [0m[1;31m197[0m[1;31m([0m[1;31m54[0m[1;31m)[0m[31m Headache [0m[1;31m152[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m [0m[1;31m([0m[1;31m23[0m[1;31m)[0m[31m Fatigue [0m[1;31m62[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m7[0m[1;31m)[0m[31m Dizziness [0m[1;31m59[0m[31m [0m[1;31m([0m[1;31m9[0m[1;31m)[0m[31m [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m Pruritus [0m[1;31m31[0m[31m [0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m Malaise[0m
[1;31m26[0m[31m [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Mood alteration [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m Somnolence [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Urticaria [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m Tinnitus [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Arthralgia [0m[1;31m9[0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m2[0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m MINOCYCLINE: adverse_reactions: Vertigo [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Dry mouth [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m
[1;31m5[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m Myalgia [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m6.2[0m[31m Postmarketing Experience Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include: Skin and hypersensitivity [0m
[31mreactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity [0m
[31mreactions, angioneurotic edema, anaphylaxis, DRESS syndrome [0m[31m. Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient [0m
[31mlupus-like syndrome. MINOCYCLINE: adverse_reactions: Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: brown-black microscopic thyroid [0m
[31mdiscoloration, abnormal thyroid function. Oncology : thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal : enterocolitis, pancreatitis, hepatitis, liver failure. Renal : [0m
[31mreversible acute renal failure. Hematology : hemolytic anemia, thrombocytopenia, eosinophilia. Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis[0m
[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Teratogenic Effects: Pregnancy Category D [0m[1;31m[[0m[31m see WARNINGS AND PRECAUTIONS [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Minocycline hydrochloride extended-release tablets should not be used [0m
[31mduring pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and [0m
[31mwell-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant [0m
[31mwoman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is [0m
[31mavailable regarding these reports; therefore, no conclusion on causal association can be established. MINOCYCLINE: pregnancy: Minocycline induced skeletal malformations [0m[1;31m([0m[31mbent limb bones[0m[1;31m)[0m[31m in fetuses [0m
[31mwhen administered to pregnant rats and rabbits in doses of [0m[1;31m30[0m[31m mg/kg/day and [0m[1;31m100[0m[31m mg/kg/day, respectively, [0m[1;31m([0m[31mresulting in approximately [0m[1;31m3[0m[31m times and [0m[1;31m2[0m[31m times, respectively, the systemic exposure to [0m
[31mminocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. Reduced mean fetal body weight was observed in studies in which minocycline was administered[0m
[31mto pregnant rats at a dose of [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride [0m
[31mextended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: pregnancy: Minocycline was assessed for effects on peri-and post-natal development of rats in a study that involved oral administration to pregnant rats from [0m
[31mday [0m[1;31m6[0m[31m of gestation through the period of lactation [0m[1;31m([0m[31mpostpartum day [0m[1;31m20[0m[1;31m)[0m[31m, at dosages of [0m[1;31m5[0m[31m, [0m[1;31m10[0m[31m, or [0m[1;31m50[0m[31m mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that [0m
[31mreceived [0m[1;31m50[0m[31m mg/kg/day [0m[1;31m([0m[31mresulting in approximately [0m[1;31m2.5[0m[31m times the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. No [0m
[31meffects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups [0m[1;31m([0m[31moffspring of animals that received [0m
[31mminocycline[0m[1;31m)[0m[31m included reduced body size, improperly rotated forelimbs, and reduced size of extremities. MINOCYCLINE: pregnancy: No effects were observed on the physical development, behavior, learning[0m
[31mability, or reproduction of F1 pups, and there was no effect on gross appearance of F2 pups [0m[1;31m([0m[31moffspring of F1 animals[0m[1;31m)[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: See “What should I tell my doctor before taking minocycline hydrochloride extended-release tablets?” • Intestine infection [0m[1;31m([0m[31mpseudomembranous colitis[0m[1;31m)[0m[31m.[0m
[31mPseudomembranous colitis can happen with most antibiotics, including minocycline hydrochloride extended-release tablets. Call your doctor right away if you get watery diarrhea, diarrhea that does not [0m
[31mgo away, or bloody stools. • Serious liver problems . Stop taking minocycline hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of liver [0m
[31mproblems: ∘ loss of appetite ∘ tiredness ∘ diarrhea ∘ yellowing of your skin or the whites of your eyes ∘ unexplained bleeding ∘ confusion ∘ sleepiness • Central nervous system effects. See “What [0m
[31mshould I avoid while taking minocycline hydrochloride extended-release tablets? MINOCYCLINE: spl_patient_package_insert: Central nervous system effects such as light headedness, dizziness, and a [0m
[31mspinning feeling [0m[1;31m([0m[31mvertigo[0m[1;31m)[0m[31m may go away during your treatment with minocycline hydrochloride extended-release tablets or if treatment is stopped. • Benign intracranial hypertension, also called [0m
[31mpseudotumor cerebri . This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking minocycline [0m
[31mhydrochloride extended-release tablets and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches. Immune system reactions including a lupus-like syndrome, [0m
[31mhepatitis, and inflammation of blood or lymph vessels [0m[1;31m([0m[31mvasculitis[0m[1;31m)[0m[31m. Using minocycline hydrochloride extended-release tablets for a long time to treat acne may cause immune system reactions. Tell your [0m
[31mdoctor right away if you get a fever, rash, joint pain, or body weakness. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to check your blood for immune system reactions. • Serious [0m
[31mrash and allergic reactions . Minocycline hydrochloride extended-release tablets may cause a serious rash and allergic reactions that may affect parts of your body such as your liver, lungs, kidneys [0m
[31mand heart. Sometimes these can lead to death. MINOCYCLINE: spl_patient_package_insert: • Stop taking minocycline hydrochloride extended-release tablets and get medical help right away if you have any [0m
[31mof these symptoms: ∘ skin rash, hives, sores in your mouth, or your skin blisters and peels ∘ swelling of your face, eyes, lips, tongue, or throat ∘ trouble swallowing or breathing ∘ blood in your [0m
[31murine ∘ fever, yellowing of the skin or the whites of your eyes, dark colored urine ∘ pain on the right side of the stomach area [0m[1;31m([0m[31mabdominal pain[0m[1;31m)[0m[31m ∘ chest pain or abnormal heartbeats ∘ swelling in your[0m
[31mlegs, ankles and feet ∘ darkening of your nails, skin, eyes, scars, teeth, and gums. The most common side effects of minocycline hydrochloride extended-release tablets include: • headache • tiredness [0m
[31m• dizziness or spinning feeling • itching Call your doctor if you have a side effect that bothers you or that does not go away. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to [0m
[31mcheck you for side effects during treatment with minocycline hydrochloride extended-release tablets. These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask [0m
[31myour doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to Sandoz Inc. at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How [0m
[31mshould I store minocycline hydrochloride extended-release tablets? • Store minocycline hydrochloride extended-release tablets at 20º to 25ºC [0m[1;31m([0m[31m68º to 77ºF[0m[1;31m)[0m[31m [0m[31m. • Keep minocycline hydrochloride [0m
[31mextended-release tablets in the container that it comes in and keep container tightly closed. • Keep minocycline hydrochloride extended-release tablets dry.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction. Additionally, the anti-anabolic action of tetracyclines, which includes minocycline, [0m
[32mmay cause an increase in BUN [0m[1;32m([0m[32mblood urea nitrogen[0m[1;32m)[0m[32m. In patients with significantly impaired renal function, higher serum levels of tetracycline-class drugs may lead to azotemia, hyperphosphatemia, and[0m
[32macidosis, potentially increasing the risk of renal failure. Therefore, if renal impairment exists, lower than usual total doses are indicated, and serum level determinations of the drug may be [0m
[32madvisable if therapy is prolonged.[0m

[32mSOURCE: Minocycline label[0m
[32mEXTRACT_START_END: [0m[1;32m5.4[0m[32m Metabolic Effects The anti-anabolic[0m[32m...[0m[32mpossible liver toxicity.[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Minocycline has been associated with reversible acute renal [0m
[34mfailure as a postmarketing adverse reaction. Additionally, the anti-anabolic action of tetracyclines, which includes minocycline, may cause an increase in BUN [0m[1;34m([0m[34mblood urea nitrogen[0m[1;34m)[0m[34m. In patients with [0m
[34msignificantly impaired renal function, higher serum levels of tetracycline-class drugs may lead to azotemia, hyperphosphatemia, and acidosis, potentially increasing the risk of renal failure. [0m
[34mTherefore, if renal impairment exists, lower than usual total doses are indicated, and serum level determinations of the drug may be advisable if therapy is prolonged.[0m

[34mSOURCE: Minocycline label[0m
[34mEXTRACT_START_END: [0m[1;34m5.4[0m[34m Metabolic Effects The anti-anabolic[0m[34m...[0m[34mpossible liver toxicity.[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if MINOCYCLINE increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information from the Minocycline label indicating that minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction."[0m[32m,[0m
[32m      [0m[32m"The label also notes that the anti-anabolic action of tetracyclines, which includes minocycline, may cause an increase in BUN, potentially increasing the risk of renal failure, especially in [0m
[32mpatients with significantly impaired renal function."[0m[32m,[0m
[32m      [0m[32m"Lower than usual total doses are indicated for patients with renal impairment, and serum level determinations of the drug may be advisable if therapy is prolonged."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction and may increase the risk of renal failure, especially in patients with [0m
[32msignificantly impaired renal function."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if MINOCYCLINE increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information from the Minocycline label indicating that minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction."[0m[34m,[0m
[34m      [0m[34m"The label also notes that the anti-anabolic action of tetracyclines, which includes minocycline, may cause an increase in BUN, potentially increasing the risk of renal failure, especially in [0m
[34mpatients with significantly impaired renal function."[0m[34m,[0m
[34m      [0m[34m"Lower than usual total doses are indicated for patients with renal impairment, and serum level determinations of the drug may be advisable if therapy is prolonged."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction and may increase the risk of renal failure, especially in patients with [0m
[34msignificantly impaired renal function."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if MINOCYCLINE increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler provided information from the Minocycline label indicating that minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction.[0m
[1;31m3[0m[31m. The label also notes that the anti-anabolic action of tetracyclines, which includes minocycline, may cause an increase in BUN, potentially increasing the risk of renal failure, especially in [0m
[31mpatients with significantly impaired renal function.[0m
[1;31m4[0m[31m. Lower than usual total doses are indicated for patients with renal impairment, and serum level determinations of the drug may be advisable if therapy is prolonged.[0m
[31m        -----[0m
[31m        Final answer: Minocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction and may increase the risk of renal failure, especially in patients with [0m
[31msignificantly impaired renal function.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mMinocycline has been associated with reversible acute renal failure as a postmarketing adverse reaction and may increase the risk of renal failure, especially in patients with significantly impaired [0m
[32mrenal function.[0m
